The GNRH1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, featuring targeted disruption of the gene encoding gonadotropin-releasing hormone (GnRH) precursor. This polyclonal pool provides a loss-of-function model that preserves cellular heterogeneity, suitable for functional studies without single-cell cloning.
The A2780 cell line originates from an untreated patient with epithelial ovarian cancer and serves as a well-established model for ovarian carcinoma biology. These cells express the GnRH receptor (GnRHR) and respond to hormonal stimuli, making them valuable for examining autocrine and paracrine GnRH actions in tumor contexts.
GNRH1 produces the decapeptide GnRH, which activates the Gq/11-coupled GnRHR on pituitary gonadotropes. Receptor engagement stimulates phospholipase C-?? (PLC-??), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), causing calcium mobilization and protein kinase C (PKC) activation. PKC, alongside other signals, triggers the RAF?CMEK?CERK1/2 kinase cascade, culminating in transcription of LHB and FSHB subunits and secretion of LH and FSH. Upstream regulators like KISS1 and steroid hormones (estradiol, progesterone) modulate GNRH1 expression, while downstream effectors include c-Fos and c-Jun transcription factors. The GnRHR also interacts with arrestins to control receptor desensitization.
In ovarian cancer, co-expression of GNRH1 and GnRHR suggests autocrine/paracrine loops that may influence tumor growth. Knocking out GNRH1 in A2780 cells permits dissection of these local signaling circuits, separate from hypothalamic-pituitary control. This model supports research into whether tumor-derived GnRH promotes proliferation, migration, or apoptosis resistance, and allows testing of GnRH analog therapies directly on cancer cells with intact vs. disrupted ligand expression.
Experimental applications encompass RT-qPCR for gonadotropin subunits, LH/FSH ELISAs, and phospho-ERK western blotting. Calcium imaging, GnRH stimulation assays, and MTS proliferation tests can assess functional outcomes, while migration, invasion, and annexin V apoptosis assays define phenotypic effects. Radioligand binding studies may characterize GnRHR pharmacology. This product is intended for reproductive biologists, oncologists, and pharmacologists exploring GnRH pathway modulation. For inquiries, contact Ascent Research.
